Curis Announces Genentech’s Initiation Of Hedgehog Antagonist Phase II Clinical Trial In Metastatic Colorectal Cancer
May 15th 2008Drug InformationColorectal Cancer
Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing the next generation of proprietary targeted medicines for cancer treatment, today announced that its collaborator Genentech has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog antagonist, in metastatic colorectal cancer. As a result, Genentech will make a $3 million cash payment to Curis under the companies’ June 2003 collaboration agreement.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
